Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers by unknown
RESEARCH ARTICLE Open Access
Using gene expression from urine sediment
to diagnose prostate cancer: development
of a new multiplex mRNA urine test and
validation of current biomarkers
Lourdes Mengual1,3*, Juan José Lozano2, Mercedes Ingelmo-Torres1, Laura Izquierdo1, Mireia Musquera1,
María José Ribal1 and Antonio Alcaraz1
Abstract
Background: Additional accurate non-invasive biomarkers are needed in the clinical setting to improve prostate
cancer (PCa) diagnosis. Here we have developed a new and improved multiplex mRNA urine test to detect prostate
cancer (PCa). Furthermore, we have validated the PCA3 urinary transcript and some panels of urinary transcripts
previously reported as useful diagnostic biomarkers for PCa in our cohort.
Methods: Post-prostatic massage urine samples were prospectively collected from PCa patients and controls.
Expression levels of 42 target genes selected from our previous studies and from the literature were studied in
224 post-prostatic massage urine sediments by quantitative PCR. Univariate logistic regression was used to
identify individual PCa predictors. A variable selection method was used to develop a multiplex biomarker model.
Discrimination was measured by ROC curve AUC for both, our model and the previously published biomarkers.
Results: Seven of the 42 genes evaluated (PCA3, ELF3, HIST1H2BG, MYO6, GALNT3, PHF12 and GDF15) were found
to be independent predictors for discriminating patients with PCa from controls. We developed a four-gene
expression signature (HIST1H2BG, SPP1, ELF3 and PCA3) with a sensitivity of 77 % and a specificity of 67 % (AUC = 0.763)
for discriminating between tumor and control urines. The accuracy of PCA3 and previously reported panels of
biomarkers is roughly maintained in our cohort.
Conclusions: Our four-gene expression signature outperforms PCA3 as well as previously reported panels of
biomarkers to predict PCa risk. This study suggests that a urinary biomarker panel could improve PCa detection.
However, the accuracy of the panels of urinary transcripts developed to date, including our signature, is not high
enough to warrant using them routinely in a clinical setting.
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Background
During the last two decades, prostate-specific antigen
(PSA) has been extensively used for prostate cancer
(PCa) screening, detection and follow-up. The routine
use of PSA has been the subject of continued contro-
versy owing to its limited specificity, which derives
from the fact that elevated serum levels of PSA occur
in a variety of non-neoplastic conditions such as pros-
tatitis and benign prostate hyperplasia (BPH) [1]. Fur-
thermore, up to 27 % of men with PSA in the normal
range (≤ 4 ng/ml) suffer from PCa [2]. The current
gold standard method for diagnosis of PCa in patients
with elevated serum PSA is non-targeted transrectal
ultrasound-guided needle biopsy, which fails to detect
PCa in approximately 20–30 % of cases [3]. Therefore,
there is a need for additional non-invasive and more
specific markers of early PCa that will permit the strati-
fication of patients according to their risk of developing
PCa and thus identify men who will require prostate
biopsy.
A great improvement in high-throughput gene ex-
pression techniques has yielded several promising mo-
lecular biomarkers for PCa detection. Prostatic cells
can be collected in urine after an intensive prostatic
massage. In 2003, Hessels et al. for the first time used
the prostate cancer antigen 3 (PCA3) for the identifica-
tion of PCa in urine sediments obtained after prostatic
massage [4]. Since then, several studies have assessed
the diagnostic performance of this marker (reviewed in
[5, 6]) and other individual transcripts [7, 8]. However,
taking into account the heterogeneity of PCa, several
authors have searched for a multiplex detection system
of biomarkers, which has proved to outperform the
diagnostic value of the individual markers [9–12].
We have previously identified new putative mRNA
markers for PCa diagnosis that can be extrapolated to
post-prostatic massage (PPM) urine samples [13]. In
the present study we aim to test several of those previ-
ously identified putative biomarkers in a large cohort of
PPM-urine samples in order to develop an improved
multiplex mRNA biomarker model for PCa diagnosis to
be routinely used in the clinical setting. Furthermore,
in our cohort we have validated the commercially avail-
able test based on urine PCA3 expression as well as the
best performing mRNA panels of biomarkers reported
in the literature [9–12].
Methods
Patients and urine samples
Under Institutional Review Board approval (Hospital
Clinic ethics committee) and patients’ informed con-
sent, we prospectively collected 273 freshly voided
urine samples from PCa patients and age matched con-
trols between January 2009 and September 2012 at the
Hospital Clínic of Barcelona. All patients underwent
radical prostatectomy. The grade and stage of the tu-
mours were determined according to Gleason criteria
and TNM classification, respectively [14, 15]. System-
atic prostate biopsy was performed to identify PCa pa-
tients included in the present study.
Voided urine samples (20 to 50 ml including the initial
portion of the urine,) were collected following prostatic
massage in sterile containers containing 2 ml of 0.5 M
EDTA, pH 8.0. Urines were immediately stored at 4 °C
and processed within the next 8 h. The samples were
centrifuged at 1000xg for 10 min, at 4 °C. The cell pel-
lets were re-suspended in 1 ml of TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) and frozen at −80 °C
until RNA extraction.
RNA extraction, cDNA synthesis and pre-amplification
RNAs from the urinary cell pellets were extracted using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions and quantified with a
NanoDrop (NanoDrop Technologies, Wilmington, DE,
USA).
cDNA was synthesized from 100 ng of total RNA
using the High Capacity cDNA reverse transcription kit
(Applied Biosystems, Foster City, CA USA; hereafter re-
ferred to as AB) following manufacturer’s instructions,
except that the final volume of the reaction was 25 μl. A
total of 1.25 μl of each cDNA sample, 2.5 μl of TaqMan
PreAmp Master Mix kit 2X (AB) and 1.25 μl of pooled
assay mix 0.2X containing 46 Gene Expression Assays
(AB) were used for the multiplex pre-amplification of
the target cDNAs following manufacturer’s instructions
(AB). The 46 assays included in the pooled assay mix
were selected from previous data from our group [13]
and literature [10, 12, 16, 17] and contains 42 target
genes and four endogenous controls; B2M, GAPHDH,
KLK2 and KLK3 (Additional file 1: Table S1). Of note,
23 of the 42 target genes selected here were previously
analyzed in urine samples by our group [13].
Quantitative PCR using BioMark 48.48 Dynamic Arrays
A total of 2.25 μl of each pre-amplified cDNA was
loaded into the Dynamic Array along with 0.25 μl of GE
Sample Loading Reagent 20X (Fuidigm) and 2.5 μl of
TaqMan Universal PCR Master Mix 2X (AB). For the as-
says, 2.5 μl of TaqMan® Gene Expression Assays 20X
(AB) were combined with 2.5 μl of Assay Loading Re-
agent and were pipetted into the assay inputs. Reaction
conditions were as follows: 50 °C for 2 min, 95 °C for
10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C
for 1 min. The real-time quantitative PCR (qPCR) experi-
ments were performed on the BioMark instrument.
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Quantitative PCR data analysis
The real-time qPCR analysis software was used to obtain
cycle quantification (Cq) values. Threshold was manually
calculated for each gene. Since experimental errors such
as inaccurate pipetting or contamination can result in
amplification curves that look significantly different from
a typical amplification curve, all amplification plots were
checked both computationally and manually. Relative
expression levels of target genes within a sample was
expressed as ΔCq (ΔCq = Cqendogenous control-Cqtarget gene).
We used as endogenous control the mean Cq value of
KLK2 and KLK3, which allowed us to normalize the pros-
tate epithelial cell content in the collected urine sample
[4]. Most of the studies seeking urinary transcripts for
PCa diagnosis have used KLK3 as a prostate-specific en-
dogenous control [4, 18, 19]. In this study, to minimize
the possibility of erroneous relative gene expression quan-
tification, we also selected KLK2 as a second prostate-
specific endogenous control since its expression level is
highly correlated with KLK3 [20].
All 273 urine samples initially included in the study
were positive for both housekeeping genes, the B2MG
(B2MG mean Cq = 8.79; range 5.07–14.58) and GAPDH
(GAPDH mean Cq = 10.85; range 7.6–16.17), indicating
that all samples contained cells. Moreover, all samples
were also positive for KLK2 (KLK2 mean Cq = 13.12;
range 9.87–17.85) and for KLK3 (KLK3 mean Cq =
12.91; range 9.58–17.65) genes, indicating that all sam-
ples contained cells of prostate origin. Cq values for all
other biomarkers are in the range for those of KLK2 and
KLK3 (data not shown). All Cq values (except 2 cases in
B2MG gene) fall in the optimal range of quantifiable Cq
values in BioMark instrument (Cq = 6 to Cq = 23) [21].
Moreover, to assure the quality of the expression data
obtained, low RNA quality samples were identified as
outliers according to their average expression by the
Mahalanobis Distance Quality Control (MDQC) method
[22] and were excluded from the study. Fold change
values were generated from the median expression of
the genes from the BioMark 48.48 Dynamic Arrays in
the groups compared.
Statistical analysis
The association of each variable with final radical prostatec-
tomy pathology results was analyzed by univariate logistic
regression. Significance was defined as p values < 0.05.
All transcripts analyzed were subjected to variable selec-
tion using the lars function with method LASSO in the
lars R statistical package (http://CRAN.R-project.org/
package=lars) [23]. As all the samples were used for the
model generation, the performance of the model may
be over-optimized. To correct this bias, we further per-
formed a leave-one-out cross-validation (LOOCV) and
100 randomisations with 5- fold cross-validation (5fCV)
(http://CRAN.R-project.org/package=rms).
The optimal probability cutoff for the univariate study
variables and logistic regression models (our model and
those previously described in the literature [9–12]) was
computed through a ROC analysis. To evaluate the per-
formance of the models, we computed sensitivity (SN),
specificity (SP), negative predictive value (NPV), positive
predictive value (PPV) and overall error rates (ER) for
the mRNA expression signature. Analysis of variance
(ANOVA) of the Risk score probability versus three
groups of PSA was done. Pairwise comparisons were
made with Tukey’s HSD procedure. R-software was used
for all calculations.
Results
Study population and informative rate
Among the 273 urine samples initially collected from
180 PCa patients and 93 control individuals, we ex-
cluded 29 urines from PCa patients (16 %) and 20 from
controls (22 %) because they were flagged as low-quality
samples when tested using MDQC method [22]. Thus,
in total, the urine samples of 224 men, 151 with PCa
and 73 controls were successfully analyzed (82 %).
Table 1 shows characteristics and clinicopathological in-
formation for the 224 evaluable subjects. Only 10 pa-
tients with PSA levels > 4 were included as controls.
Pathological reports from these patients confirmed the
absence of malignity at the time of sample collection
and they have not presented PCa during a mean follow-
up of 45.6 months (range 19.5 to 78.9).
Development of a new multiplex mRNA model
All 42 selected genes were first tested by univariate lo-
gistic regression analysis, with 7 genes (PCA3, ELF3,
HIST1H2BG, MYO6, GALNT3, PHF12 and GDF15)
showing significant association for discriminating PCa
patients from control individuals (Table 2 and Additional
file 2: Table S2). Notably, no significant differences in
TMPRSS2-ERG status between tumor (mean Cq = 13.54;
range 10.28–18.21) and control (mean Cq = 13.88; range
10.28–18.71) urine samples were found. Differences in Cq
values for TMPRSS2-ERG across the different Gleason
stages (mean Cq = 13.54 for Gleason ≤ 6; mean Cq = 13.64
for Gleason = 7; mean Cq = 13.27 for Gleason ≥ 8) were
not found either.
To evaluate the performance of individual markers for
diagnosing PCa, we performed a ROC analysis (Table 2).
Then, individual biomarkers were subjected to variable
selection to develop a multiplex model that could im-
prove performance over single biomarkers. This analysis
resulted in a final selection of a four-gene model that
contains HIST1H2BG, SPP1, ELF3 and PCA3. The four
gene model outperformed single genes and previously
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reported models in the literature in detecting PCa in
urinary sediments (SN = 77 %; SP = 67 %; PPV = 83 %;
NPV = 58 %; ER = 26 %; AUC = 0.763). After applying
LOOCV analysis to the four-gene model, we obtained a
SN of 79 % for discriminating between tumor and con-
trol urines with a SP of 60 % (PPV = 80 %; NPP = 58 %;
ER = 27 %; AUC 0.735). By using 5fCV analysis, we
found a SN of 72.52 % for discriminating between tumor
and control urines with a SP of 64.83 % (PPV = 80.86 %;
NPV = 53.5 %; ER = 30 %; AUC 0.732) (Fig. 1a). To note,
the four-gene model also performs well in the diagnostic
PSA gray-zone (PSA 3–10 ng/ml) yielding a SN of 79 %
for discriminating between tumor urines from patients
with PSA serum values between 3 and 10 ng/ml and
control urines, with a SP of 59 % (PPV = 72 %; NPP =
68 %; ER = 29 %; p < 0.001) (Fig. 1b).
Evaluation of previously reported diagnostic biomarkers
of urinary transcripts in our cohort
First, we evaluated the PCA3 marker (TaqMan PCR test
for PCA3) as a single marker. Univariate logistic regres-
sion analysis showed that expression of PCA3 was a sig-
nificant discriminator of PCa from control individuals
(p < 0.01). PCA3 alone achieved an overall SN of 49 %
and a SP of 85 % (AUC = 0.708) to discriminate controls
from PCa urines (Table 2 and Additional file 2: Table S2).
Then, we evaluated in our cohort some of the most po-
tentially promising PCa diagnostic panels of urinary
transcripts reported in the literature, to validate their
performance in an independent set. Table 3 summarizes
the diagnostic performance of the biomarkers panels in
our case-control setting in comparison to the results
obtained in the original studies. As shown, all the bio-
marker combinations roughly maintain their performance
when tested in an independent set, the combination de-
scribed by Laxman et al. (2008) having the best perform-
ance [10].
Discussion
Currently, PSA is considered the most valuable tool in
the early detection, staging and monitoring of PCa.
However, as mentioned in the introduction, PSA has
several limitations as a PCa diagnostic biomarker, espe-
cially in deciding the necessity of a prostate biopsy. Ac-
tually, PCa is detected in only about a third of patients
with elevated serum PSA who undergo random prostate
biopsy. Repeated biopsies reveal the presence of PCa in
another 10–35 % of the cases [24]. Not only economic
aspects but also anxiety, discomfort, and sometimes se-
vere complications are associated with prostate biopsies.
Therefore, the development of a non-invasive diagnostic
tool for the early detection and screening of PCa as well
as to increase the probability of detecting PCa at repeat
biopsy, reducing the number of unnecessary biopsies, is
needed in urological practice. Detection of aberrantly
expressed transcripts in PCa cells shed into the urine
after prostatic massage are promising biomarkers for the
development of a reliable non-invasive PCa diagnostic
method. In fact, several promising RNA-based urine
PCa biomarkers are described in the literature, but only
the PCA3 assay (Progensa) is approved by the FDA and
currently is the only molecular diagnostic assay for PCa
commercially available. However, PCA3 is not routinely
used in the clinical setting mainly because clinicians feel
that the increase in accuracy over serum PSA testing is
Table 1 Clinicohistopathologic features of the studied
population
Tumor urine samples
Mean ± SD (range)
Age (yr) 67.5 ± 7.9 (45–85)
Gland weight (g)a 48.21 ± 22.88 (16–180)
Serum PSA (ng/ml)b 13.76 ± 36.1 (0.94–365)
Levels N patients (%)
PSA (ng/ml)b 0–4 6 (4)
4–10 96 (65)
> 10 46 (31)
Gleason scorec < 7 69 (46)
≥ 7 81 (54)










Mean ± SD (range)
Age (yr) 67.2 ± 12 (21–97)





Urethral stenosis 4 (5)
Others 11 (15)
Abbreviations: SD Standard Deviation, RP Radical prostatectomy, RT
Radiotherapy, CRT Cryotherapy, AS Active surveillance, HT Hormonal therapy,
BPH Benign Prostate Hyperplasia, LUTS Low Urinary Tract Symptom
aData available for 98 PCa patients; bData available for 148 PCa patients; cData
available for 150 PCa patients; dData available for 113 PCa patients. Stage T1,
only for those patients with no pathological stage available (Eg. RT, CRT, AS
and HT); eData available for 65 controls
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not significant enough to warrant a biopsy. Further-
more, since PCa is a heterogeneous disease, it is rea-
sonable that a combination of markers outperforms
single marker detection. In this regard, several authors
have described combinations of RNA-markers in urine
samples but to our knowledge, none of them, except
one [25], has been externally validated nor is currently
used in the clinical setting. In the present work, we
have developed a four-gene panel that outperforms
those previously described in the literature. In addition,
in our cohort we have validated PCA3 as well as the
most promising panels of biomarkers described.
Table 2 Univariate logistic regression and ROC analyses of the biomarkers
Variable Fold
change
Univariate logistic regression analysis ROC analysis
OR (95 % CI) p value AUC (95 % CI)
PCA3 1.331 4.106 (7.534–2.237) <0.01* 0.708 (0.742–0.675)
ELF3 −1.676 0.637 (0.818–0.496) <0.01* 0.657 (0.693–0.621)
MYO6 −1.270 0.561 (0.826–0.381) 0.003* 0.622 (0.659–0.585)
HIST1H2BG −1.243 0.609 (0.852–0.435) 0.004* 0.613 (0.65–0.575)
GALNT3 −1.064 0.556 (0.955–0.324) 0.033* 0.583 (0.622–0.545)
PHF12 −1.074 0.68 (0.982–0.471) 0.04* 0.567 (0.606–0.528)
GDF15 −1.240 0.681 (0.995–0.466) 0.047* 0.594 (0.632–0.556)
PTOV1 −1.110 0.615 (1.028–0.368) 0.063 0.592 (0.63–0.554)
PSMA 1.108 1.99 (4.153–0.954) 0.067 0.59 (0.628–0.552)
SPINK1 −1.156 0.74 (1.046–0.524) 0.089 0.572 (0.611–0.534)
SOX4 −1.148 0.663 (1.065–0.413) 0.089 0.571 (0.61–0.533)
KLK12 −1.142 0.639 (1.091–0.375) 0.101 0.577 (0.615–0.538)
SLC44A5 −1.090 0.646 (1.122–0.372) 0.121 0.57 (0.609–0.532)
SPP1 1.241 1.126 (1.335–0.95) 0.171 0.543 (0.582–0.504)
DLX1 −1.169 0.718 (1.16–0.444) 0.175 0.562 (0.601–0.523)
CTHRC1 −1.178 0.724 (1.157–0.453) 0.177 0.556 (0.595–0.518)
TOX3 −1.057 0.677 (1.198–0.383) 0.18 0.56 (0.599–0.522)
TRPM4 −1.130 0.69 (1.217–0.391) 0.2 0.554 (0.592–0.515)
ELAVL2 −1.068 0.734 (1.186–0.454) 0.207 0.554 (0.593–0.515)
TWIST1 −1.120 0.744 (1.19–0.466) 0.217 0.558 (0.6–0.52)
Abbreviations: OD odds ratio, 95 % CI 95 % confidence interval, AUC Area Under the Curve
*Statistically significant (p < 0.05)
Note: Only biomarkers presenting a p value < 0.25 are listed. Univariate logistic regression and ROC analysis for all biomarkers is shown in Additional file 2: Table S2
Fig. 1 Diagnostic performance of the four –gene expression signature. a ROC analysis based on the predicted probabilities derived from the four-gene
model. b Probabilistic sensitivity analysis of the signature according to serum PSA levels
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From our analysis, we have been able to identify six
new candidates that independently predict PCa in PPM-
urine samples, besides PCA3. This has been possible
since we have explored target genes selected from pre-
vious PCa microarray data [13, 17] instead of analyzing
only previously described prostate related biomarkers.
Actually, all target genes explored were used to develop
the four-gene set model that contains the previously
described PCA3 gene and three new biomarkers:
HIST1H2BG, SPP1 and ELF3. This model outperforms
individual biomarkers and previously reported models
in the literature. Although LOOCV indicates a certain
degree of overfitting, all data obtained after cross valid-
ation corroborate the SN and SP for the final model.
Moreover, the model performs well in the diagnostic
PSA gray-zone (PSA 3–10 ng/ml) where a reduction in
the number of unnecessary biopsies is necessary.
Notably, the three new biomarkers of the model had
been previously associated with PCa. Alterations in
expression of histone HIST1H2BG were associated with
biochemical recurrence in PCa patients after radical
prostatectomy [26]. The transcription factor ELF3
(E74-like factor 3), that acts as a negative modulator of
androgen receptor transcriptional activity, was found
underexpressed in PCa [27], according to our results.
On the other hand, SPP1 (secreted phosphoprotein 1)
encodes the protein osteopontin (OPN). Both, OPN
RNA and protein have been found overexpressed in a
number of human tumor types, including PCa [28]. In
some cases, OPN overexpression has been shown to be
associated directly with poor patient prognosis or with
other indicators of poor prognosis. Thus, OPN has a
dual interest, as a biomarker of malignancy as well as a
candidate for testing as a poor prognostic factor. Even
though in the present study we did not achieve statis-
tical significance for SPP1, the addition of this gene to
the model improved the AUC from 0.740 (HIST1H2BG,
PCA3 and ELF3) to 0.763 (SPP1, HIST1H2BG, PCA3
and ELF3), indicating that effectively its expression
adds information to the model.
The present study confirms that PCA3 can success-
fully discriminate PCa from controls in randomly
selected patients with variable PSA levels (PSA = 0.94–
365 ng/ml) [29, 30]. A limitation of most studies based
on urinary biomarkers is that the negative PCa patient
group consists of patients who have undergone pros-
tate biopsy for suspected PCa with a negative result,
but in fact, 20–30 % of such patients will be diagnosed
with PCa at a later date [3]. To overcome this limita-
tion, our control group consisted of patients without
suspected PCa (PSA < 4.0 ng/ml), thus minimizing the
risk of including subjects with PCa in the control
group. Moreover, there is no uniform methodological
protocol for urinary transcript quantification in the
reported studies. For instance, some studies use a
multiplex cDNA preamplification step before qPCR
transcript quantification [16, 31], while others use a
Whole Transcriptome Amplification [10, 32] or even
in some studies cDNA is not preamplifed [11]. Also
different gene expression normalization methods are
used [4, 11, 16, 18, 31]. Thus, it is notable that despite
this methodological heterogeneity and the inherent
limitations of the sample source (PPM-urine contains
different cell types, including renal tubular cells, urothelial
cells, prostate cells, etc.… and the proportion of prostate
tumor cells in each subject is different), we and the vast
majority of the groups identify PCA3 as an independent
predictor for PCa diagnosis, making it the most reliable
individual biomarker to date.
However, combining urinary biomarkers in a panel has
shown higher diagnostic accuracy than PCA3 alone. Re-
garding this, we have been able to validate some of the
previously reported panels of biomarkers [9–12] in our
cohort and to develop a new urinary panel of biomarkers
that improves serum PSA and previously reported panels
of biomarkers. On the contrary, we could not validate
differences between control and cancer population for
the TMPRSS2-ERG status. This is in all probability due
to the methodological approach used here, since others
using the same methodology as us (RT-qPCR using the
Table 3 Diagnostic performance for PCa of the most significant urine-gene expression signatures containing PCA3 gene, reported
originally and validated in our cohort
Study Biomarkers Initial performance reported Performance validation (our cohort)
n total (T/C) SN (%) SP (%) AUC n total (T/C) SN (%) SP (%) AUC
Hessels et al., 2003 [4] PCA3 108 (24/84) 67 83 0.717 224 (151/73) 49 85 0.708
Hessels et al., 2007 [9] PCA3, TMPRSS2:ERG 108 (78/30) 73 52 - 224 (151/73) 48 86 0.708
Laxman et al., 2008 [10] PCA3, TMPRSS2:ERG, GOLPH2, SPINK1 234 (138/96) 66 76 0.758 224 (151/73) 72 64 0.719
Ouyang et al., 2009 [11] PCA3, AMACAR 92 (43/49) 81 53 - 224 (151/73) 48 85 0.707
Rigau et al., 2010 [12] PCA3, PSGR 215 (73/142) 77 60 0.73 224 (151/73) 62 71 0.708
Present study, 2015 HIST1H2BG, SPP1, ELF3 and PCA3 224 (151/73) 77 83 0.763 224 (151/73) 77 83 0.763
Abbreviations: T Tumors, C Controls, SN Sensitivity, SP Specificity, AUC Area Under the Curve
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same gene expression assay as us; Hs03063375_ft ) to
evaluate TMPRSS2-ERG status also did not find differ-
ences between cancer and control urines [33] while other
authors using Southern blot [9] or transcription-mediated
amplification [32] were able to find such differences.
Of concern, neither the FDA approved PCA3 test
alone, or in combination with other biomarkers, is being
routinely used in the clinical setting. This is most likely
because the addition of urine biomarkers to the current
clinical diagnostic tools only shows a limited improve-
ment in the PCa diagnosis accuracy and does not pro-
vide sufficient value to affect biopsy decision making. In
fact, recently the Evaluation of Genomic Applications in
Practice and Prevention Working Group (EWG) has
found insufficient evidence to recommend PCA3 testing
not only for deciding to conduct initial biopsies for PCa
at risk men (e.g. previously elevated PSA test or suspi-
cious digital rectal examination) but also for deciding
when to rebiopsy previously biopsy-negative patients
for PCa. Furthermore, the EWG did not find convin-
cing evidence to recommend PCA3 testing in men with
PCa positive-biopsies to determine whether the disease
is indolent or aggressive, in order to develop an optimal
treatment plan [34]. Thus, even though many efforts
have been made in the last decade to identify urine bio-
markers that determine men at high risk of PCa and
whether the disease is indolent or aggressive in men with
PCa, the results do not seem convincing for clinicians.
We acknowledge that our study has several limitations.
First it resides in the relatively low sample size of the
studied cohort. This was because 18 % of urine samples
collected could not be evaluated (informative specimen
rate of 82 %). Although some improvements in the
methodological process would be desirable to decrease
the percentage of fails, this percentage is in the range of
those described by other authors who quantify gene ex-
pression in PPM urine samples (informative specimen
rates 56 to 92 %) [10–12, 16, 30, 31]. However, sample
collection can be repeated if necessary. It could also be
argued that we arbitrarily selected the 42 target genes,
while the list of differentially expressed genes in PCa is
much larger. In this regard, we have tried to include the
biomarkers according to previous studies, as being either
detectable in urine or appropriate for combined models,
and genes highly differentially expressed in PCa tissue
samples. We are also aware that we should test the per-
formance of our four-gene expression signature in a real
clinical scenario by analyzing patients who undergo
prostate biopsy for suspected PCa, even though this
study will have the limitation of false negative biopsies,
which account for 20–30 % of men at risk of PCa [3].
Lastly, future validation studies are needed to further
improve the performance of this test by examination of
larger and independent cohorts.
Conclusions
We report a four-gene expression signature with higher
diagnostic accuracy than PCA3, the only non-invasive
commercially available urinary biomarker, to predict in-
dividuals at risk of PCa. Moreover, our four-gene expres-
sion signature outperforms previously reported panels of
biomarkers for PCa detection. Taken together, these re-
sults suggest that new biomarkers can be successfully
combined with PCA3, resulting in improvements in PCa
detection. However, further sources of new non-invasive
biomarkers that enable physicians to accurately predict
any PCa at initial prostate biopsy and aggressive PCa
should be explored.
Additional files
Additional file 1: Table S1. Commercial Gene Expression Assays from
Life Technologies used in this study. Target exons for transcript detection
as well as amplicon length for each trasncrip are shown. (DOCX 18 kb)
Additional file 2: Table S2. Univariate logistic regression and ROC
analyses of the biomarkers. (DOCX 19 kb)
Abbreviations
5fCV: 5-fold cross-validation; AUC: area under curve; BPH: benign prostate
hyperplasia; CI: confidence interval; Cq: cycle quantification; ER: error rate;
LOOCV: leave-one-out cross-validation; NPV: negative predictive value;
OD: odds ratio; PCa: prostate cancer; PPM: post-prostatic massage;
PPV: positive predictive value; PSA: Prostate-specific antigen;
qPCR: quantitative PCR; ROC: receiver operator characteristic; SD: standard
deviation; SN: sensitivity; SP: specificity.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LM participated in study concept and design, acquisition and analysis of
data, drafting of the manuscript and supervision of the study conduct. JJL
participated in study concept and design, analysis of data, critical revision of
the manuscript and statistical analysis. MIT participated in acquisition and
analysis of data, critical revision of the manuscript and supervision of the
study conduct. LI and MM participated in acquisition of data and critical
revision of the manuscript. MJR participated in study concept and design,
analysis of data, critical revision of the manuscript and supervision of the
study conduct. AA participated in study concept and design, analysis of data,
critical revision of the manuscript and supervision of the study conduct. All
authors read and approved the final manuscript.
Acknowledgements
We thank the patients for their collaboration and all the staff from the
Urology Departments and nurses from Hospital Clínic for collaborating in the
sample collection. This work was supported by grants from Laboratorios FINA
BIOTECH, Ministerio de Economia y Competividad (IPT-2012-1311-300000) and
Fundación para la Investigación en Urología (FIU 2010).
Author details
1Laboratory and Department of Urology, Hospital Clínic, Institut
d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de
Barcelona, Barcelona, Spain. 2CIBERehd. Plataforma de Bioinformática, Centro
de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas,
Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer
(IDIBAPS), Universitat de Barcelona, Barcelona, Spain. 3Laboratory of Urology,
Hospital Clínic, Centre de Recerca Biomèdica CELLEX, office B22, C/Casanova,
143, 08036 Barcelona, Spain.
Mengual et al. BMC Cancer  (2016) 16:76 Page 7 of 8
Received: 2 November 2014 Accepted: 4 February 2016
References
1. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The
prostate specific antigen era in the United States is over for prostate cancer:
what happened in the last 20 years? J Urol. 2004;172:1297–301.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev
V, Mottet N, van der kwast TH, Wiegel T, Zattoni F. Guidelines on Prostate
Cancer. In: European Association of Urology Guidelines. edition presented at
the 28th EAU Annual Congress edition. members of the European
Association of Urology (EAU) Guidelines Office, editor. Milan: 2013. https://
uroweb.org/guidelines/.
3. Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, et al.
Performance of transperineal template-guided mapping biopsy in detecting
prostate cancer in the initial and repeat biopsy setting. Prostate Cancer
Prostatic Dis. 2010;13:71–7.
4. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ,
van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the
diagnosis of prostate cancer. Eur Urol. 2003;44:8–15.
5. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer.
Nat Rev Urol. 2009;6:255–61.
6. Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood
based prostate cancer biomarkers: a review. Clin Biochem. 2014;47:889–96.
7. Zielie PJ, Mobley JA, Ebb RG, Jiang Z, Blute RD, Ho SM. A novel diagnostic test
for prostate cancer emerges from the determination of alpha-methylacyl-
coenzyme a racemase in prostatic secretions. J Urol. 2004;172:1130–3.
8. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, et al.
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of
men with prostate cancer. Neoplasia. 2006;8:885–8.
9. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA.
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3
in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer
Res. 2007;13:5103–8.
10. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al. A first-
generation multiplex biomarker analysis of urine for the early detection of
prostate cancer. Cancer Res. 2008;68:645–9.
11. Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM. A duplex
quantitative polymerase chain reaction assay based on quantification of
alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in
urine sediments improved diagnostic accuracy for prostate cancer. J Urol.
2009;181:2508–13.
12. Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, et al. PSGR
and PCA3 as biomarkers for the detection of prostate cancer in urine.
Prostate. 2010;70:1760–7.
13. Mengual L, Ars E, Lozano JJ, Burset M, Izquierdo L, Ingelmo-Torres M, Gaya
JM, Algaba F, Villavicencio H, Ribal MJ, Alcaraz A. Gene expression profiles in
prostate cancer: Identification of candidate non-invasive diagnostic markers.
Actas Urol Esp. 2014;38:143–9.
14. Sobin LH, Gospodariwicz M, Wittekind CH. TNM Classification of Malignant
Tumours. UICC International Union Against Cancer. New York: Wiley; 2009.
15. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. The 2005 International
Society of Urological Pathology (ISUP) Consensus Conference on Gleason
Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29:1228–42.
16. Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llaurado M, et al.
A three-gene panel on urine increases PSA specificity in the detection of
prostate cancer. Prostate. 2011;71:1736–45.
17. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al.
Integrative genomic and proteomic analysis of prostate cancer reveals
signatures of metastatic progression. Cancer Cell. 2005;8:393–406.
18. Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, et al. Evaluation of
the ETS-related gene mRNA in urine for the detection of prostate cancer.
Clin Cancer Res. 2010;16:1572–6.
19. Ouyang B, Leung YK, Wang V, Chung E, Levin L, Bracken B, et al. alpha-
Methylacyl-CoA racemase spliced variants and their expression in normal
and malignant prostate tissues. Urology. 2011;77:249. e1-7.
20. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and
biological fluids. Clin Chem. 2007;53:1423–32.
21. Sorg D, Danowski K, Korenkova V, Rusnakova V, Kuffner R, Zimmer R, et al.
Microfluidic high-throughput RT-qPCR measurements of the immune
response of primary bovine mammary epithelial cells cultured from milk to
mastitis pathogens. Animal. 2013;7:799–805.
22. Cohen Freue GV, Hollander Z, Shen E, Zamar RH, Balshaw R, Scherer A, et al.
MDQC: a new quality assessment method for microarrays based on quality
control reports. Bioinformatics. 2007;23:3162–9.
23. Efron B, Johnstone I, Hastie T, Tibshirani R. Least angle regression (with
discussion). Ann Stat. 2004;32:407–99.
24. Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeat prostate
biopsy: who, how and when? A review. Eur Urol. 2002;42:93–103.
25. Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke
TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-
van de Kaa CA, Schalken JA. Prospective Multicentre Evaluation of PCA3 and
TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary
Biomarkers for Prostate Cancer. Eur Urol. 2014;65:534–42.
26. Chen X, Xu S, McClelland M, Rahmatpanah F, Sawyers A, Jia Z, et al. An accurate
prostate cancer prognosticator using a seven-gene signature plus Gleason score
and taking cell type heterogeneity into account. PLoS One. 2012;7:e45178.
27. Shatnawi A, Norris JD, Chaveroux C, Jasper JS, Sherk AB, McDonnell DP,
Giguere V. ELF3 is a repressor of androgen receptor action in prostate
cancer cells. Oncogene. 2014;33:862–71.
28. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K,
Perruzzi CA, et al. Osteopontin expression and distribution in human
carcinomas. Am J Pathol. 1994;145:610–23.
29. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et
al. Clinical utility of the PCA3 urine assay in European men scheduled for
repeat biopsy. Eur Urol. 2008;54:1081–8.
30. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, et
al. The time-resolved fluorescence-based PCA3 test on urinary sediments
after digital rectal examination; a Dutch multicenter validation of the
diagnostic performance. Clin Cancer Res. 2007;13:939–43.
31. Jamaspishvili T, Kral M, Khomeriki I, Vyhnankova V, Mgebrishvili G, Student V,
et al. Quadriplex model enhances urine-based detection of prostate cancer.
Prostate Cancer Prostatic Dis. 2011;14:354–60.
32. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al.
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to
predict diagnosis of prostate cancer. Urol Oncol. 2013;31:566–71.
33. Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masia E,
Casanova J, et al. Identification of miR-187 and miR-182 as biomarkers of
early diagnosis and prognosis in patients with prostate cancer treated with
radical prostatectomy. J Urol. 2014;192:252–9.
34. Recommendations from the EGAPP Working Group: does PCA3 testing for
the diagnosis and management of prostate cancer improve patient health
outcomes? Genet Med. 2014; 16:338–46.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mengual et al. BMC Cancer  (2016) 16:76 Page 8 of 8
